Literature DB >> 24915143

PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.

Ellen M McDonagh1, Caroline F Thorn, John T Callaghan, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24915143      PMCID： PMC4122637          DOI： 10.1097/FPC.0000000000000058

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  116 in total

1.  Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong.

Authors:  M L S Chiu; M Hu; M H L Ng; C K Yeung; J C-Y Chan; M M Chang; S H Cheng; L Li; B Tomlinson
Journal:  Br J Dermatol       Date:  2012-05-08       Impact factor: 9.302

2.  Methemoglobinemia.

Authors:  S Curry
Journal:  Ann Emerg Med       Date:  1982-04       Impact factor: 5.721

3.  Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.

Authors:  C H Pui
Journal:  Semin Hematol       Date:  2001-10       Impact factor: 3.851

4.  Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans.

Authors:  Hye-Ryun Kang; Young Koo Jee; Yon-Soo Kim; Chang Hwa Lee; Jae-Woo Jung; Sae Hoon Kim; Heung-Woo Park; Yoon-Seok Chang; In-Jin Jang; Sang-Heon Cho; Kyung-Up Min; Sang-Heon Kim; Kyung Wha Lee
Journal:  Pharmacogenet Genomics       Date:  2011-05       Impact factor: 2.089

5.  HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese.

Authors:  Zhi-hao Cao; Zhi-yun Wei; Qin-yuan Zhu; Jun-yu Zhang; Lun Yang; Sheng-ying Qin; Li-yan Shao; Yi-ting Zhang; Jie-kun Xuan; Qiao-li Li; Jin-Hua Xu; Feng Xu; Li Ma; Hui-yuan Huang; Qing-he Xing; Xiao-qun Luo
Journal:  Pharmacogenomics       Date:  2012-07       Impact factor: 2.533

6.  Effect of sulphinpyrazone (Anturan) on uric acid excretion and plasma uric acid concentration in healthy volunteers.

Authors:  B Pfister; P Imhof; H Wirz
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

7.  [A severe G6PD deficiency revealed during a chemotherapy protocol including rasburicase].

Authors:  P Joly; C Bon; A Francina; M-C Gelineau; P Lacan; H Orfeuvre
Journal:  Ann Biol Clin (Paris)       Date:  2009 Jul-Aug       Impact factor: 0.459

Review 8.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 9.  Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA.

Authors:  J Yun; J Adam; D Yerly; W J Pichler
Journal:  Allergy       Date:  2012-09-03       Impact factor: 13.146

10.  The IMGT/HLA database.

Authors:  James Robinson; Kavita Mistry; Hamish McWilliam; Rodrigo Lopez; Peter Parham; Steven G E Marsh
Journal:  Nucleic Acids Res       Date:  2010-11-11       Impact factor: 16.971
View more
  9 in total

Review 1.  Hyperuricemia, Type 2 Diabetes Mellitus, and Hypertension: an Emerging Association.

Authors:  Ibrahim Mortada
Journal:  Curr Hypertens Rep       Date:  2017-09       Impact factor: 5.369

Review 2.  The effect of allopurinol on cardiovascular outcomes in patients with type 2 diabetes: a systematic review.

Authors:  Evanthia Bletsa; Stavroula A Paschou; Vasiliki Tsigkou; Panagiota K Stampouloglou; Vasiliki Vasileiou; Georgia N Kassi; Evangelos Oikonomou; Gerasimos Siasos
Journal:  Hormones (Athens)       Date:  2022-10-05       Impact factor: 3.419

Review 3.  Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.

Authors:  Samir G Mallat; Sahar Al Kattar; Bassem Y Tanios; Abdo Jurjus
Journal:  Curr Hypertens Rep       Date:  2016-10       Impact factor: 5.369

4.  Uric Acid and Neurocognitive Function in Survivors of Childhood Acute Lymphoblastic Leukemia Treated with Chemotherapy Only.

Authors:  Yin Ting Cheung; Michelle N Edelmann; Daniel A Mulrooney; Daniel M Green; Wassim Chemaitilly; Neena John; Leslie L Robison; Melissa M Hudson; Kevin R Krull
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-06-26       Impact factor: 4.254

Review 5.  Hypouricemia: what the practicing rheumatologist should know about this condition.

Authors:  Carlos Pineda; Carina Soto-Fajardo; Jaime Mendoza; Jessica Gutiérrez; Hugo Sandoval
Journal:  Clin Rheumatol       Date:  2019-10-24       Impact factor: 2.980

6.  Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management--A KDIGO consensus report.

Authors:  Kai-Uwe Eckardt; Seth L Alper; Corinne Antignac; Anthony J Bleyer; Dominique Chauveau; Karin Dahan; Constantinos Deltas; Andrew Hosking; Stanislav Kmoch; Luca Rampoldi; Michael Wiesener; Matthias T Wolf; Olivier Devuyst
Journal:  Kidney Int       Date:  2015-03-04       Impact factor: 10.612

7.  Serum uric acid levels during leprosy reaction episodes.

Authors:  Yvelise T Morato-Conceicao; Eduardo R Alves-Junior; Talita A Arruda; Jose C Lopes; Cor J F Fontes
Journal:  PeerJ       Date:  2016-03-14       Impact factor: 2.984

Review 8.  Uric Acid and Arterial Stiffness.

Authors:  Adriana Albu; Ioana Para; Mihai Porojan
Journal:  Ther Clin Risk Manag       Date:  2020-01-28       Impact factor: 2.423

Review 9.  Renal effects of uric acid: hyperuricemia and hypouricemia.

Authors:  Jung Hwan Park; Yong-Il Jo; Jong-Ho Lee
Journal:  Korean J Intern Med       Date:  2020-09-09       Impact factor: 2.884
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.